HUE027280T2 - Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére - Google Patents

Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére Download PDF

Info

Publication number
HUE027280T2
HUE027280T2 HUE11186078A HUE11186078A HUE027280T2 HU E027280 T2 HUE027280 T2 HU E027280T2 HU E11186078 A HUE11186078 A HU E11186078A HU E11186078 A HUE11186078 A HU E11186078A HU E027280 T2 HUE027280 T2 HU E027280T2
Authority
HU
Hungary
Prior art keywords
angiotensin
receptor
antagonist
treatment
cats
Prior art date
Application number
HUE11186078A
Other languages
English (en)
Inventor
Marcus Stark
Ulrike Sent
Ingo Lang
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE027280(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of HUE027280T2 publication Critical patent/HUE027280T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (4)

  1. ÄagiöiesÄ^il^receptisr aniagonlsiák macskák magas vérnyomásának kezelésére SzabadalMi igénypontok L terápiásán katéfeíw meróyiségá aiïgmtëîmm-II-meepior-! (AT-l) .wáa^mstát tartalmazó gyógyászati készítmény macskák szisztémás magas vérnyomásának kezelésére szolgáló gyógyszerként történő alkalnrazásra, ahol az angkOenAn-II-receptor-l (AX-I) anta|pemsla egy sarian-vegyälet % Az 1 > igénypont szériáik terápiásán hatékony mennyiségi angiotenzm-l^eeepoc-l <AT*I)" antagonisíáé tartalmazó gyógyászati készítmény az igényeit gyógyszerkém Pártén© alkalmazásra* ától «. vérnyomás vesebeíegségekke! magas vér nyomás.
  2. 3. Az 1, vagy %. igénypont szerinti, terápiásán hatékony mennyiségi angiotenzío-II-receptor-1 | A1>I) ant^onistát tartalmazó gyógyászai készítmény az igényi gyógyszerként történő alkalmazásra, ahol az attgiotenzin-II-reeeptor-l (AT4) antagonism a következőkből álé csoportból van kiválasztva; caoóésaAám ejMsarfan,, irbesarían, losaAan, tasosartan, iehrnsartan, válsartaa és ezek gyógyászatüag elfogadható sói.
  3. 4. Az 1-3. igénypontok szerinti, terápiásán hatékony nteonyiségü angiotenzimíí-meeptor-1 (AI-!) antagonists tartalmazó gyógyászait készítmÉty az igényeit gyógyszerként történ© alkalmazásra, almi az angiotenzin-íl-reeeptóf-l (AT-II antagonists a telrmsartan.
  4. 5. Az '1-4. igénypontok bármelyiké szerinti, terápiásm hatékony mennyiségiangioíenzln:- Il^reeeptOAl -itóÉnazé gyógyászod készítmény az igényeit gyógyszer ként történő alkalmazásra, ahol az angiotenzíivII-receptor-l (AT-I) antagonists. terápiásán hatékony mennyisége 0,01-5,0 mgÓesítómegAg,. é. Az 1-5. igénypontok bármelyike szériml terápiásán hatékony mennyiségi angiotenzm-! Ι-receptor-! (Α'Γ-l) antagonistât tartalmazó gyógyászati készítmény az igényeli gyógyszerként történd alkalmazásra, ahol m gyógyászati készítmény egy arra rászoruló ógyeonek #,014 mg âniiotenÂ-il-receptor-I (AT-1) antagomsia/testtömeg-kg dózisban paremeráismt vágy 0,€β-5,0 mg iangiÓíenzin-II-recepíor-i: (AT-1) antagomsia/testtömeg-kg dózisban orálisan, rékíáhsan, nazálisán vagy belélegeztetéssef adagolók.
HUE11186078A 2006-10-06 2007-10-04 Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére HUE027280T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06121905A EP1908469A1 (en) 2006-10-06 2006-10-06 Angiotensin II receptor antagonist for the treatment of systemic diseases in cats

Publications (1)

Publication Number Publication Date
HUE027280T2 true HUE027280T2 (hu) 2016-09-28

Family

ID=37744125

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE11186078A HUE027280T2 (hu) 2006-10-06 2007-10-04 Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére
HUE11186070A HUE027399T2 (hu) 2006-10-06 2007-10-04 Angiotenzin II receptor antagonista macskák kardiovaszkuláris betegségének kezelésére
HUS1300062C HUS1300062I1 (hu) 2006-10-06 2013-10-21 Angiotenzin II receptor antagonista szisztémás betegségek kezelésére macskákban
HUS1800044C HUS1800044I1 (hu) 2006-10-06 2018-11-08 Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE11186070A HUE027399T2 (hu) 2006-10-06 2007-10-04 Angiotenzin II receptor antagonista macskák kardiovaszkuláris betegségének kezelésére
HUS1300062C HUS1300062I1 (hu) 2006-10-06 2013-10-21 Angiotenzin II receptor antagonista szisztémás betegségek kezelésére macskákban
HUS1800044C HUS1800044I1 (hu) 2006-10-06 2018-11-08 Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére

Country Status (25)

Country Link
US (5) US8772278B2 (hu)
EP (5) EP1908469A1 (hu)
JP (5) JP5425631B2 (hu)
KR (2) KR101456151B1 (hu)
CN (6) CN114344293B (hu)
AR (1) AR063155A1 (hu)
BR (4) BRPI0718041A2 (hu)
CA (1) CA2665435C (hu)
CL (2) CL2007002897A1 (hu)
CO (1) CO6180425A2 (hu)
CY (2) CY1114266T1 (hu)
DK (4) DK2420231T3 (hu)
ES (4) ES2567041T3 (hu)
HR (1) HRP20130696T1 (hu)
HU (4) HUE027280T2 (hu)
LU (1) LU92282I2 (hu)
MX (4) MX360147B (hu)
NL (1) NL300616I2 (hu)
NZ (3) NZ609533A (hu)
PL (4) PL2420233T3 (hu)
PT (1) PT2086535E (hu)
SI (1) SI2086535T1 (hu)
TW (3) TWI539950B (hu)
WO (1) WO2008040774A2 (hu)
ZA (1) ZA200901218B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
WO2010097501A2 (en) * 2009-02-26 2010-09-02 Orion Corporation A combination treatment
DK2432452T3 (en) 2009-05-20 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutically telmisartan drink solution
CN102283832B (zh) * 2011-09-09 2013-04-10 南京正宽医药科技有限公司 一种预防或治疗高血压肥胖患者的药物组合物及用途
SG10201609364QA (en) 2012-05-18 2017-01-27 Luoda Pharma Pty Ltd Liquid formulation
DE102012018903A1 (de) 2012-09-26 2014-03-27 Elisabeth Kurth Brustglocke für die manuelle Laktation von Milch aus der weiblichen Brust
CN105233288A (zh) * 2015-09-28 2016-01-13 青岛云天生物技术有限公司 一种治疗或预防肥胖型高血压的药物组合物及其用途
JP6800633B2 (ja) * 2016-07-04 2020-12-16 株式会社カネカ 非ヒト動物において腎機能の低下を抑制する方法
KR20200026975A (ko) * 2017-07-07 2020-03-11 베링거잉겔하임베트메디카게엠베하 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1023027B (de) 1953-07-10 1958-01-23 Hoffmann La Roche Verfahren zur Herstellung von Polyendialdehyden
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4448778A (en) 1981-08-03 1984-05-15 Ici Americas Inc. Maltitol containing gel base systems
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE59107440D1 (de) 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
GB9027210D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
US5591762A (en) 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
ES2135472T3 (es) 1992-04-13 1999-11-01 Zeneca Ltd Antagonistas de angiotensina ii contra trastornos asociados con la velocidad de conduccion neuronal deteriorada, especialmente la neuropatia diabetica.
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
JP3883205B2 (ja) 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ｉｉ▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
MX9707683A (es) * 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
CA2257946A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
ES2214013T3 (es) 1998-03-04 2004-09-01 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
US6204281B1 (en) * 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
DE19901921C2 (de) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
EP1389105A4 (en) * 2001-05-14 2005-08-17 Merck & Co Inc METHOD OF TREATMENT
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
CA2486121A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2003268219B2 (en) * 2002-08-28 2009-09-24 Barnes-Jewish Hospital Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
DE10244681A1 (de) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
WO2005123070A1 (en) * 2004-06-09 2005-12-29 Fibrogen, Inc. Dual blockade of renin-angiotensin system reduces connective tissue growth factor levels in diabetic nephropathy
CN1602960A (zh) * 2004-07-23 2005-04-06 海南国栋药物研究所有限公司 一种防治心脑血管病及糖尿病等代谢综合症的复合制剂
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
DK1814527T4 (da) * 2004-11-05 2020-12-07 Boehringer Ingelheim Int Dobbeltlagstablet omfattende telmisartan og amlodipin
CN1813707A (zh) * 2004-12-01 2006-08-09 鲁南制药集团股份有限公司 用于治疗高血压的含有单硝酸异山梨酯的药物组合物
US20070026026A1 (en) * 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP1970053A1 (en) 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
DK2432452T3 (en) 2009-05-20 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutically telmisartan drink solution

Also Published As

Publication number Publication date
KR101456151B1 (ko) 2014-11-04
ZA200901218B (en) 2010-03-31
JP2017122115A (ja) 2017-07-13
CL2007002897A1 (es) 2008-03-07
EP2420231B1 (en) 2016-01-13
JP6151123B2 (ja) 2017-06-21
LU92282I9 (hu) 2019-01-17
CN114344293B (zh) 2024-04-19
CN102512678A (zh) 2012-06-27
NZ576109A (en) 2012-02-24
US9585873B2 (en) 2017-03-07
EP2420231A2 (en) 2012-02-22
US20140288138A1 (en) 2014-09-25
CN101522191B (zh) 2012-05-16
TW200831078A (en) 2008-08-01
JP5425631B2 (ja) 2014-02-26
EP2420232A3 (en) 2012-05-02
SI2086535T1 (sl) 2013-09-30
AU2007304216A1 (en) 2008-04-10
EP2420232B1 (en) 2016-01-06
CN101522191A (zh) 2009-09-02
HRP20130696T1 (hr) 2013-09-30
EP2420233A2 (en) 2012-02-22
JP2010505796A (ja) 2010-02-25
EP2086535B1 (en) 2013-05-22
MX360147B (es) 2018-10-24
EP2420231A3 (en) 2012-04-11
KR101529541B1 (ko) 2015-06-17
BR122013019534A2 (pt) 2015-07-14
JP2016094436A (ja) 2016-05-26
CA2665435A1 (en) 2008-04-10
PL2420231T3 (pl) 2016-07-29
EP2420233B1 (en) 2016-01-13
NL300616I2 (hu) 2016-06-01
TWI539950B (zh) 2016-07-01
EP2086535A2 (en) 2009-08-12
DK2420231T3 (en) 2016-04-11
ES2565519T3 (es) 2016-04-05
BR122013019535A2 (pt) 2015-07-14
CY2013037I2 (el) 2015-11-04
US20080146543A1 (en) 2008-06-19
MX360150B (es) 2018-10-24
CY2013037I1 (el) 2015-11-04
MX360148B (es) 2018-10-24
KR20140088601A (ko) 2014-07-10
JP5899165B2 (ja) 2016-04-06
ES2567041T3 (es) 2016-04-19
US20130190373A1 (en) 2013-07-25
PL2420233T3 (pl) 2016-07-29
US10357479B2 (en) 2019-07-23
TW201402115A (zh) 2014-01-16
BRPI0718041A2 (pt) 2015-05-12
AU2007304216B2 (en) 2013-06-13
JP2013216709A (ja) 2013-10-24
WO2008040774A2 (en) 2008-04-10
DK2420232T3 (en) 2016-03-07
CN109125730A (zh) 2019-01-04
BR122013019533A2 (pt) 2015-07-14
PL2086535T3 (pl) 2013-10-31
PT2086535E (pt) 2013-08-22
TWI415605B (zh) 2013-11-21
LU92282I2 (fr) 2013-11-19
US9949954B2 (en) 2018-04-24
CY1114266T1 (el) 2015-11-04
WO2008040774A3 (en) 2008-07-10
CA2665435C (en) 2016-03-29
JP6337170B2 (ja) 2018-06-06
CN114344293A (zh) 2022-04-15
EP1908469A1 (en) 2008-04-09
HUS1300062I1 (hu) 2013-11-28
DK2420233T3 (en) 2016-04-11
NZ609533A (en) 2014-08-29
US20180193317A1 (en) 2018-07-12
JP2013216708A (ja) 2013-10-24
MX2009002340A (es) 2009-03-23
US8772278B2 (en) 2014-07-08
TWI539949B (zh) 2016-07-01
KR20090080954A (ko) 2009-07-27
CN102580095A (zh) 2012-07-18
HUE027399T2 (hu) 2016-09-28
AR063155A1 (es) 2008-12-30
HUS1800044I1 (hu) 2018-12-28
US20170128423A1 (en) 2017-05-11
NZ597648A (en) 2013-05-31
CN102580095B (zh) 2015-12-09
CO6180425A2 (es) 2010-07-19
ES2562182T3 (es) 2016-03-02
EP2420233A3 (en) 2012-04-18
PL2420232T3 (pl) 2016-06-30
TW201332547A (zh) 2013-08-16
ES2425482T3 (es) 2013-10-15
CL2012001349A1 (es) 2012-10-12
CN105148272A (zh) 2015-12-16
US9308197B2 (en) 2016-04-12
DK2086535T3 (da) 2013-07-22
EP2420232A2 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
US10357479B2 (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
US20210106564A1 (en) Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
AU2007304216B9 (en) Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
AU2013203932B2 (en) Angiotensin II receptor antagonist for the treatment of systemic diseases in cats